Endocrine immune-related adverse event is a prognostic biomarker independent of lead-time bias

Immune checkpoint inhibitors (ICIs), including anti-programmed cell death protein 1 (anti-PD-1), anti-programmed cell death protein –ligand 1 (anti-PD-L1), and anti-cytotoxic T-lymphocyte antigen 4 (anti-CTLA4) antibodies, have been approved for patients with advanced or recurrent non-small cell lung cancer (NSCLC) [1–9]. However, ICIs often cause immune-related adverse events (irAEs), potentially leading to discontinuation of the treatment. A meta-analysis demonstrated that treatment discontinuation due to irAE may affect the outcome of the patient [10].

Source: Lung Cancer - April 9, 2024 Category: Cancer & Oncology Authors: Mina Ishidoya, Tomonori Makiguchi, Hisashi Tanaka, Toko Miura, Yasuhito Nunomura, Dai Miura, Takeshi Morimoto, Yukihiro Hasegawa, Kageaki Taima, Sadatomo Tasaka Tags: Research Paper Source Type: research